泰励生物将在 AACR 2024 展示已获 FDA IND 批准的 KRAS G12D 抑制剂 TSN1611 临床前研究结果

上海，2024年3月20日 – 泰励生物（Tyligand Bioscience），一家致力于开发针对耐药肿瘤创新疗法的临床阶段的生物技术公司，宣布将出席 2024 年 4 月 5 日至 10 日举行的美国癌症研究协会（AACR）年会。届时，泰励生物将介绍 TSN1611 的临床前研究成果（Poster# 3315）。

TSN1611 是泰励生物自主研发的一种靶向携带 KRAS G12D 突变肿瘤的高效高选择性小分子药物，该突变是多种恶性肿瘤进展的关键驱动因素。TSN1611 的口服制剂已获美国食品药品监督管理局（FDA）批准进行临床试验，这是开发该潜在疗法的重要一步。

“临床前研究表明，TSN1611 有望改善 KRAS G12D 肿瘤患者的治疗现状。我们很高兴能与科学和医学界分享我们的发现。” 泰励生物首席执行官张彦涛（Tony Zhang）博士表示，“我们将致力于全速高质量地推进这个药物的开发，以期及早造福全球癌症患者。”

KRAS 突变是最常见的致癌突变之一，而靶向其中最普遍的 G12D 突变更具挑战性。尽管近年来癌症研究和治疗取得了重大进展，但 KRAS 驱动的肿瘤仍带来重大的未满足医疗需求，凸显了创新治疗方案的迫切性。

AACR 2024 年会上展示的数据将表明 TSN1611 在抑制 KRAS G12D 靶点方面所呈现的良好成药性，以及动物体内疗效和安全性。FDA 的 IND 批准标志着 TSN1611 在临床上评估其安全性和有效性的历程上迈出了重要的一步。

‍‍‍‍‍‍‍‍关于泰励生物科技（上海）有限公司

泰励生物（Tyligand Bioscience）成立于2018年，是一家临床阶段生物技术公司，专注于癌症创新疗法的发现和开发。除了正积极推向全球临床试验的 TSN1611 外，公司临床管线还包括 II 型多靶点激酶抑制剂 TSN084、首个双功能肿瘤免疫激动剂 (DATIA®) TSN222，以及具有独特连接子和新颖有效负载的抗体药物偶联物（ADC）研发平台。

有关Tyligand Bioscience的更多信息，请访问 www.tyligand.com‍‍‍‍‍‍‍‍‍‍

Tyligand Bioscience to Present Preclinical Study Results of TSN1611, a potent, selective, and orally bioavailable KRAS G12D Inhibitor at AACR 2024, following FDA’s IND Clearance

Shanghai, March 20th, 2024 – Tyligand Bioscience, a clinical-stage biotechnology company dedicated to developing innovative therapeutics against drug resistant tumors, announces its participation at the 2024 American Association for Cancer Research (AACR) Annual Meeting on April 5-10, San Diego, where it will present results of preclinical studies of TSN1611(Poster# 3315), a potent and selective small molecule inhibitor targeting tumors harboring KRAS G12D mutation, a pivotal driver of cancer progression in numerous malignancies. On Feb 14th, an oral formulation of TSN1611 has received clearance from the U.S. Food and Drug Administration (FDA) for clinical trials, an essential step forward in the development of this promising therapy.

“Preclinical studies indicate that TSN1611 has the potential to make a meaningful difference in the lives of patients with KRAS G12D driven cancers, and we are excited to share our findings with the scientific and medical community,” said Tony Zhang, Ph.D., CEO of Tyligand Bioscience. “We remain committed to advancing its development with quality and speed for the global cancer patients in need”.

KRAS mutations are among the most prevalent oncogenic alterations in cancer patients, with the G12D mutation being one of the most challenging to target effectively. Despite significant advances in cancer research and therapy, KRAS-driven cancers present a substantial unmet medical need, underscoring the urgency for innovative treatment options.

The preclinical data to be presented by Tyligand Bioscience at AACR 2024 demonstrates the promising efficacy and safety profile of TSN1611 in inhibiting KRAS G12D. FDA’s IND approvals marks the achievement of an important milestone in advancing TSN1611 towards clinical evaluations for its safety and efficacy.   

About Tyligand Bioscience (Shanghai) Limited

Founded in 2018, Tyligand Bioscience is a clinical stage biotech focusing on the discovery and development of transformative therapies for cancer. In addition to the KRAS G12D program, the company has several molecules in development, including TSN084, a Type II multi-kinase inhibitor; TSN222, a first in kind dual acting tumor immune agonist (DATIA®), and a platform for antibody drug conjugates (ADCs) featuring proprietary linkers and novel payloads.

For more information about Tyligand Bioscience, please visit www.tyligand.com

陆舜教授、张剑教授、黑永疆博士、谢雨礼博士、邱杨博士、顾薇女士、花海清博士、胡朝红博士、朱梅英博士精彩分享！| 药时代视频荟萃

“绊倒”药王，有时只需一个联合疗法

9款药物折戟NASH/MASH领域